Abstract Library

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study

Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sansovini M

Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,

Keywords: PRRT, FDG-PET, P-NET,

#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs

Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Severi S

Authors: Stefano S, Maddalena S, Ianniello A, Nicolini S, Caroli P,

Keywords: PRRT, GEP-NET, re-treatment,

#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).

Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sansovini M

Authors: Sansovini M, Stefano S, Ianniello A, Nicolini S, Fantini L,

Keywords: PRRT, neuroendocrine, FDG-PET,

#1042 The Challenge of Differential Diagnosis of Solid Pancreatic Lesions in Von Hippel-Lindau. Case Report

Introduction: Von Hippel-Lindau (VHL) is an hereditary syndrome, characterized by a predisposition to develop benign and malignant tumors. Pancreatic involvement is present in 35-70% of cases and include cystic (simple cyst, serous cystoadenoma, mucinous tumor or IPMN) and solid lesions (neuroendocrine neoplasm (NEN), metastatic mass or pancreatic adenocarcinoma). Finally, a solid-type serous cystoadenoma (SSCA) has been reported. Differential diagnosis of these lesions may be difficult.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Zilli A

Authors: Zilli A, Cavalcoli F, Maddalena P, Conte D, Massironi S,

Keywords: solid pancreatic lesions, VHL,